Breaking News, Collaborations & Alliances

Natera, Fox Chase Cancer Center Partner for Oncology

To assess Signatera™ (Research-Use Only) customized circulating tumor DNA assay for recurrence monitoring of kidney cancer

Natera, Inc. has partnered with Fox Chase Cancer Center, one of the leading cancer centers in the United States, to assess the company’s Signatera™ (Research-Use Only) customized circulating tumor DNA (ctDNA) assay for recurrence monitoring of kidney cancer.  The study will analyze biological specimens collected and banked from 49 patients diagnosed with kidney cancer—including a group whose cancer recurred and a group that did not recur after three years or more. The study will use Nat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters